PMU17 - RETROSPECTIVE STUDY OF PATIENTS USING ELBASVIR/GRAZOPREVIR IN FRANCE

ZEPATIER® (elbasvir/grazoprevir; EBR/GZR) is a direct-acting antiviral drug for chronic C hepatitis (HCV). As the patterns of use of EBR/GZR in routine medical practice is little documented, the objective was to describe patients receiving EBR/GZR in real-world practice in France, as well as treatment duration. The national health insurance information system database lists all in and outpatient healthcare consumption for individuals covered by the national health system. All patients initiating EBR/GZR between January 1 and June 30, 2017 were identified in the database and followed until June 30, 2017. The outcomes were patient’s baseline characteristics, the duration of EBR/GZR treatment, as well as management of care, medical contacts and co-medications of interest in the 12 months prior to EBR/GZR initiation. A total of 2,337 patients initiating EBR/GZR were analysed (mean age of 55.7 years (SD=12.8); 50.9% females; 23.1% with deprived socio-economic status). In the 12 months prior to initiation of EBR/GZR, 37.5% of patients had a fibroscan and 39.1% had one or more biological fibrosis score. Psychiatric disorders and diabetes were found in 11.0% and 8.0% of patients, respectively. A completed treatment course follow-up was available for 951 patients. The mean duration of EBR/GZR was 78.5 days (SD=18.1) and the median was 84 days. Among these patients, 1.7% had received another treatment for HCV in the 12 months before the initiation of EBR/GZR. Sub-group of patients with HCV-HIV co-infection accounted for 4.3% and sub-group of patients receiving substitution treatments (methadone or buprenorphine) for 6.6%. This study identified 2,337 patients initiating EBR/GZR, and 951 patients had a completed treatment course defined. The median duration of EBR/GZR treatment was close to recommendations (84 days, or 12 weeks). Data will be confirmed on a larger numbers of patients, with a longer follow-up period.